INDIANAPOLIS, March 14, 2023 /PRNewswire/ -- Eli Lilly and Company LLY today announced that data from its oncology portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, April 14 – 19, 2023. …
BlackRock Advisors, LLC ("BlackRock") will host a conference call on Wednesday, March 15, 2023 at 2:00pm ET featuring Phil Ruvinsky, Head of BlackRock's U.S. Growth Team and the Portfolio Manager for BlackRock Innovation and Growth Trust (…
First Quarter 2023 Highlights - comparisons to the prior year quarter Net earnings per diluted share increased 22% to $2.06 Decreased 21% to $2.12, excluding mark-to-market losses on technology investments in both years Net earnings increased 18% to …
- Interim results from Phase 2 innovaTV 207 trial of tisotumab vedotin in head and neck cancer to be presented - - Initial Phase 1 dose-escalation data for SEA-TGT monotherapy in advanced malignancies to be disclosed - - Preclinical data and discovery …
– Clinical trial in progress to be presented for Phase 1a/b study investigating AB248 alone and in combination with pembrolizumab in patients with advanced solid tumors – – Preclinical data for cis-targeted IL-2 and IL-21 cytokines that selectively …
HALIFAX, NS / ACCESSWIRE / March 14, 2023 / Today, MedMira Inc. (MedMira) MIR provides an update on its progress to achieve regulatory approval in Canada for its Reveal® TP (Syphilis) antibody test. The Company has successfully started its …
PRINCETON, NJ / ACCESSWIRE / March 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. SONN ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that data from the company- …
Eleven abstracts accepted for poster presentation highlight company's differentiated antibody drug conjugate, multispecific antibody, and clinical product candidates Management will host a conference call on April 18th at 6:30 pm Eastern Standard Time …
Flare Therapeutics Inc., a private biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced that it will give an oral presentation highlighting the discovery of its clinical …
Awarded $448 million contract with the United States Navy as part of joint venture; Year-to-date contract wins total over $582 million Announces three point strategic plan to continuously improve financial performance HOUSTON, March 14, 2023 (GLOBE …
Xencor, Inc. XNCR, a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on novel XmAb® CD28 bispecific antibody …
SOUTH SAN FRANCISCO, Calif., March 14, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. IDYA, a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced publication …
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. ERAS, a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced …
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, March 14, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises First Republic Bank (“First Republic” or “the Company”) (NYSE: FRC) investors that the …
Accelerating the March Toward Health Equity WASHINGTON , DC, UNITED STATES, March 14, 2023 /EINPresswire.com/ -- The National Medical Association (NMA) is hosting its annual National Colloquium on African American Health, March 24-27, 2023, in …
BALTIMORE and PALO ALTO, Calif., March 14, 2023 /PRNewswire/ -- Delfi Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, will present multiple oral and …
GARDEN CITY, N.Y. and HAMILTON, Bermuda, March 14, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. XAIR that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced …
NORWOOD, Mass., March 14, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. CRBP ("Corbus" or the "Company"), a precision oncology company, today announced that an abstract highlighting pre-clinical data for CRB-601, its avβ8 …
- Reports $64.1 Million of Revenue, Growth of 24% Year-Over-Year - Insurance Segment continues strong growth, with atypical fourth-quarter weather impacting Adjusted EBITDA SEATTLE, March 14, 2023 (GLOBE NEWSWIRE) -- Porch Group, Inc. ("Porch Group…
BURLINGAME, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. CRVS, a clinical-stage biopharmaceutical company, today announced that it will present new data for CPI-818, the Company's ITK inhibitor, at the American Association …
